in

Coronavirus company news summary – US purchases 200m extra doses of Moderna’s Covid-19 vaccine

The US government has procured an additional 200 million doses of Moderna’s Covid-19 vaccine, including the option to buy other Covid-19 vaccine products from the company’s pipeline. The US government has procured a total of 500 million doses of the Moderna vaccine to date, including the delivery of 110 million doses by the end of 2021, and 90 million doses in the first quarter of 2022.

The Canadian government has allocated approximately $1.75m towards a study that will evaluate the safety and efficacy of Covid-19 vaccination for people with HIV, through the Covid-19 Immunity Task Force and the Vaccine Surveillance Reference Group. People living with HIV lack adequate immune response to diseases, and as a result, are vulnerable to Covid-19 illnesses and reduced response to Covid-19 vaccination. The study has received an additional funding of $2.6m from the Canadian Institutes for Health Research, Stop the Spread Ottawa and the CIHR Canadian HIV Trials Network.

The UMass Medical School will begin enrolling 100 participants from the initial Pfizer trial into a Covid-19 vaccine booster study by the end of June, according to the principal investigator of an ongoing trial of Pfizer-BioNTech’s Covid-19 vaccine. The booster dose is expected to be administered about six months after participants received the second dose of the original vaccine. The Phase III trial will include 10,000 people from across the world who will be randomised to take a placebo or a third dose of the same vaccine. Researchers are expected to divide the study over two groups, those aged 16 to 55 years and adults aged above 55 years.

Reference